Verapamil and Doxorubicin Resistance in Melanoma Cells
Author Information
Author(s): F. Formelli, R. Supino, L. Cleris, M. Mariani
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
Does the combination of verapamil and doxorubicin increase the rate of resistance development in B16 melanoma cells?
Conclusion
The study found that combining verapamil with doxorubicin increases the rate at which B16 melanoma cells develop resistance to doxorubicin.
Supporting Evidence
- The combination of verapamil and doxorubicin led to a faster development of drug resistance in B16 melanoma cells.
- Cells treated with doxorubicin alone developed resistance after 27 transplants, while those treated with both drugs did so after only 17.
- Lung metastases were significantly lower in the B16-DX.VRP line compared to the original B16 melanoma.
- Verapamil was shown to enhance the cytotoxicity of doxorubicin in resistant cell lines.
Takeaway
When doctors give a medicine called doxorubicin to fight cancer, adding another medicine called verapamil can make the cancer cells stronger and harder to kill.
Methodology
The study involved both in vitro and in vivo experiments with B16 melanoma cells treated with doxorubicin and verapamil, assessing resistance development through various transplant passages.
Limitations
The study primarily focused on a single type of melanoma cell line, which may limit the generalizability of the findings.
Participant Demographics
C57BL/6 male mice were used for in vivo studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website